Tianjin Lisheng Pharmaceutical Co.,Ltd.

SZSE:002393 Stock Report

Market Cap: CN¥4.5b

Tianjin Lisheng PharmaceuticalLtd Valuation

Is 002393 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002393 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002393 (CN¥18.4) is trading above our estimate of fair value (CN¥13.13)

Significantly Below Fair Value: 002393 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002393?

Key metric: As 002393 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002393. This is calculated by dividing 002393's market cap by their current earnings.
What is 002393's PE Ratio?
PE Ratio25x
EarningsCN¥188.41m
Market CapCN¥4.49b

Price to Earnings Ratio vs Peers

How does 002393's PE Ratio compare to its peers?

The above table shows the PE ratio for 002393 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37x
603207 Shanghai Xiao Fang PharmaceuticalLtd
22.1xn/aCN¥4.3b
603676 Tibet Weixinkang Medicine
17.7xn/aCN¥4.3b
603566 Pulike Biological Engineering
44.7x33.1%CN¥4.4b
002728 Teyi Pharmaceutical GroupLtd
63.6x47.2%CN¥4.4b
002393 Tianjin Lisheng PharmaceuticalLtd
25xn/aCN¥4.5b

Price-To-Earnings vs Peers: 002393 is good value based on its Price-To-Earnings Ratio (25x) compared to the peer average (37x).

Price to Earnings Ratio vs Industry

How does 002393's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
002393 25.0xIndustry Avg. 29.9xNo. of Companies30PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 002393 is good value based on its Price-To-Earnings Ratio (25x) compared to the CN Pharmaceuticals industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 002393's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002393 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 002393's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.84

7D

-3.9%

1Y

14.4%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.44

7D

-2.0%

1Y

18.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥22.24

7D

2.3%

1Y

23.4%